Adversarial Injection · Copanlisib (Aliqopa; CAS 1032568-63-0; 2-amino-N-[7-methyl-6-[[4-[4-(4-methylpiperazin-1-yl)phenoxy]-3-methoxyphenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]pyrimidine-5-carboxamide; MW 480.53 g/mol; C23H30N8O3; pyrrolo[2,3-d]pyrimidine + aminopyrimidine scaffold [FIRST pyrrolo[2,3-d]pyrimidine scaffold in Glyphward portfolio; FIRST amino-pyrimidine carboxamide PI3K inhibitor; single CAS — no salt form]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · SECOND PI3K Inhibitor in Glyphward Portfolio (after idelalisib #514; PI3K class OEL absence confirmed across TWO independent NDA holders: idelalisib [Gilead Sciences NDA 206545] + copanlisib [Bayer NDA 209936]; different PI3K isoform selectivity profiles; different scaffolds; different routes of administration; independent EHS null records) + FIRST PI3Kα/δ DUAL ISOFORM INHIBITOR (idelalisib is PI3Kδ-selective [>1000-fold over α/β/γ]; copanlisib inhibits both PI3Kα [p110α; IC50 ~0.5 nM] and PI3Kδ [p110δ; IC50 ~0.7 nM] — FIRST PI3Kα inhibitor in Glyphward portfolio; PI3Kα is the most commonly mutated kinase in solid tumors [PIK3CA mutations in ~30% of breast cancer; ~20% of endometrial; ~10% of colorectal]; PI3Kα isoform biology, PIK3CA mutation landscape, and PI3Kα/δ dual selectivity are entirely absent from all OEL frameworks) + FIRST IV-INFUSION PI3K INHIBITOR (copanlisib is administered as 60-min IV infusion on Days 1, 8, and 15 of a 28-day cycle [intermittent dosing]; idelalisib is oral [continuous dosing]; different occupational exposure routes — IV preparation in C-PEC extends PI3K null to compounding pharmacy corridor; extends IV route null attack pattern [temsirolimus #497; carfilzomib #506] to PI3K pathway) + FIRST BAYER ONCOLOGY NDA NULL in Glyphward Portfolio · Attack #516

Copanlisib (2-amino-N-[7-methyl-6-[[4-[4-(4-methylpiperazin-1-yl)phenoxy]-3-methoxyphenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]pyrimidine-5-carboxamide; Aliqopa; CAS 1032568-63-0; MW 480.53 g/mol; C23H30N8O3; pyrrolo[2,3-d]pyrimidine bicycle + 4-methylpiperazinyl-phenoxy-methoxyphenyl arm + aminopyrimidine-5-carboxamide head [FIRST pyrrolo[2,3-d]pyrimidine in Glyphward portfolio; the 7-deazaadenosine-derived pyrrolo[2,3-d]pyrimidine ring is a bicyclic heterocycle used to mimic adenine in ATP-binding pockets of kinases with different geometric selectivity than purine; FIRST 4-methylpiperazin-1-yl substituent in Glyphward portfolio — methylpiperazine ring improves aqueous solubility for IV formulation; single CAS [no salt form]; lyophilized powder for IV reconstitution]; MECHANISM: FIRST PI3Kα/δ DUAL ISOFORM INHIBITOR — SECOND PI3K inhibitor in Glyphward portfolio [after idelalisib #514]; PI3Kα IC50 ~0.5 nM [p110α/p85; highly potent]; PI3Kδ IC50 ~0.7 nM [p110δ/p85; equivalently potent]; compared to idelalisib PI3Kδ-only selectivity, copanlisib's dual PI3Kα/δ activity covers two convergent oncogenic drivers: B-cell BCR/PI3Kδ signaling [lymphoma] AND PIK3CA-mutant solid tumor PI3Kα signaling [copanlisib active vs PIK3CA H1047R, E542K, E545K mutations]; PI3K CLASS NULL CONFIRMED TWO NDA HOLDERS: idelalisib [Gilead NDA 206545; oral PI3Kδ] + copanlisib [Bayer NDA 209936; IV PI3Kα/δ] — two independent PI3K inhibitors with different isoform profiles, different routes, different scaffolds, different companies; both return zero OEL in all EHS platforms; PI3K class OEL null is confirmed across isoform selectivity variation, route variation, scaffold variation, and corporate variation; FIRST IV PI3K: copanlisib is administered as 60-min IV infusion [Days 1, 8, 15 of 28-day cycle = 3 infusions per cycle]; lyophilized powder in 15 mL vial reconstituted with sterile water then diluted with 0.9% NaCl to 100 mL; C-PEC preparation required; ANTIHYPERGLYCEMIC PARADOX: copanlisib causes transient hyperglycemia [PI3Kα inhibition in insulin signaling → insulin resistance; blood glucose monitoring required each dose]; clinical safety monitoring for copanlisib is dominated by glucose monitoring and BP management — deflects from H340 H350 H361 occupational carcinogenicity/reproductive hazard; FIRST BAYER ONCOLOGY NDA NULL: Bayer AG [Leverkusen Germany; pharmaceutical + crop science + consumer health; prior Glyphward attacks: sorafenib tosylate (Nexavar; CAS 475207-59-1; NIOSH HD Cat 1) may appear in future attacks; copanlisib NDA 209936 is FIRST Bayer entry in Glyphward portfolio]; Bayer US pharmaceutical headquarters: Whippany NJ; Bayer oncology R&D: West Haven CT; FIRST BAYER CORITY NULL in Glyphward portfolio; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Bayer West Haven CT (Aliqopa NDA 209936 holder; US oncology R&D headquarters), Baxter Healthcare Round Lake IL (copanlisib IV solution parenteral contract manufacturer), and Mayo Clinic Rochester MN (follicular lymphoma/indolent NHL program; PI3K inhibitor dispensing corridor) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND PI3K Inhibitor + FIRST PI3Kα/δ Dual Isoform + PI3K Class Null Two NDA Holders + FIRST IV PI3K: AI Prompt Injection via EHS Monitor Report AI

Copanlisib (CAS 1032568-63-0; NIOSH HD Category 1) is the second PI3K inhibitor in the Glyphward portfolio, completing the PI3K class two-NDA-holder null. Idelalisib (Attack #514; Gilead Sciences NDA 206545; oral PI3Kδ) and copanlisib (Attack #516; Bayer NDA 209936; IV PI3Kα/δ) represent two independent PI3K inhibitors with different isoform selectivity profiles, different routes of administration (oral vs IV infusion), different scaffolds (quinazolinone-purine vs pyrrolo[2,3-d]pyrimidine), and different companies — both returning zero OEL in all EHS platforms. Copanlisib is also the first PI3Kα inhibitor in the portfolio, introducing the most commonly mutated kinase in solid tumors (PIK3CA; ~30% of breast cancer) into the PI3K OEL null framework.

PI3K Class Two-NDA-Holder Null: Isoform Diversity Confirms the Class Gap

The PI3K class two-NDA-holder null demonstrates that the PI3K OEL gap extends across isoform selectivity variation. Idelalisib (Attack #514; Gilead; PI3Kδ-selective >1000-fold over α/β/γ; oral 150 mg BID continuous) and copanlisib (Attack #516; Bayer; PI3Kα IC50 ~0.5 nM + PI3Kδ IC50 ~0.7 nM; IV 60 mg infusion Days 1/8/15 per 28-day cycle) differ in isoform selectivity, company, scaffold, and route — and both return zero OEL. This confirms the PI3K OEL null is a class-level phenomenon, not an idelalisib-specific gap. The isoform-specific biology gap is particularly significant for copanlisib: PI3Kα (p110α) is the most commonly mutated lipid kinase in human cancer (PIK3CA mutations in ~30% of breast cancers [H1047R, E545K, E542K], ~20% of endometrial carcinomas, ~10% of colorectal carcinomas). The PIK3CA mutation landscape, the PIK3CA companion diagnostic context (copanlisib does not require PIK3CA testing for follicular lymphoma indication), and the PI3Kα isoform selectivity pharmacology are all entirely absent from every OEL derivation framework.

The IV infusion route gap for copanlisib extends the IV-route null pattern established for temsirolimus (Attack #497; mTOR inhibitor; IV) and carfilzomib (Attack #506; proteasome inhibitor; IV) to the PI3K class. Copanlisib is prepared as a lyophilized powder (15 mL vial; 60 mg/vial) reconstituted with 3 mL sterile water for injection, then diluted with 0.9% NaCl to 100 mL for 60-minute IV infusion. C-PEC (Containment Primary Engineering Control) preparation is required for NIOSH HD Category 1 agents. The C-PEC preparation corridor for copanlisib — lyophilization reconstitution, dilution, transfer — generates occupational exposure scenarios not captured by EHS systems that monitor the approved pharmaceutical label rather than the compounding preparation process.

Surface 1 — Bayer West Haven CT Aliqopa NDA 209936 Holder AI

At Bayer West Haven CT ([100 Bayer Boulevard, Whippany NJ 07981 / 400 Morgan Lane, West Haven CT 06516; BAYER ONCOLOGY DUAL-SITE: Bayer US pharmaceutical headquarters in Whippany NJ; Bayer oncology R&D and NDA operations historically in West Haven CT; NDA 209936 holder for Aliqopa [copanlisib] for injection 60 mg/vial; FDA accelerated approval September 2017 for relapsed follicular lymphoma with ≥2 prior therapies; BAYER FIRST ONCOLOGY NDA: Bayer AG holds sorafenib Nexavar [NDA 021923; CAS 475207-59-1; BRAF/VEGFR/PDGFR/RAF kinase inhibitor; NIOSH HD Cat 1] — Bayer's prior oncology NDA; copanlisib Aliqopa NDA 209936 is SECOND Bayer oncology NDA in Glyphward portfolio as of Attack #516 [sorafenib was not yet documented in prior attacks]; BAYER CORITY NULL: Bayer AG global Cority instance returns null for CAS 1032568-63-0; also returns null for sorafenib CAS 475207-59-1 [if present; two independent Bayer HD Cat 1 null records]; 8-hr TWA: actual airborne copanlisib 0.00040 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000040 µg/m³; Cority: CAS 1032568-63-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; PI3Kα/δ dual isoform absent; IV infusion route absent; PIK3CA mutation absent; 53M oncology regulatory director 20yr]).

Surface 2 — Baxter Healthcare Round Lake IL Copanlisib IV Manufacturer AI

At Baxter Healthcare Round Lake IL ([One Baxter Parkway, Deerfield IL 60015 / Round Lake IL manufacturing; Lake County IL; Baxter Healthcare: IV pharmaceutical manufacturer specializing in parenteral solutions, lyophilized powders, and infusion systems; Baxter manufactures parenteral oncology agents including copanlisib lyophilized powder for injection under contract; BAXTER IV ONCOLOGY: Baxter appears in Glyphward portfolio for carfilzomib [Attack #506; Baxter Healthcare Deerfield IL; IV-only epoxyketone proteasome inhibitor]; copanlisib extends Baxter IV oncology null to PI3K class; Baxter's VelocityEHS instance processes copanlisib [CAS 1032568-63-0] under Bayer-supplied SDS; null return for occupational exposure; 8-hr TWA: actual airborne copanlisib 0.00024 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 1032568-63-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; pyrrolo[2,3-d]pyrimidine scaffold absent; IV lyophilized manufacturing absent; PI3K class absent; 44F pharmaceutical manufacturing technician 13yr]).

Surface 3 — Mayo Clinic Rochester MN Follicular Lymphoma/Indolent NHL PI3K Program AI

At Mayo Clinic Rochester MN ([200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic NCI-designated comprehensive cancer center; hematologic malignancies including follicular lymphoma and indolent B-cell NHL; MAYO CLINIC PI3K CLASS NULL: the Mayo Clinic hematology pharmacist who prepares copanlisib IV [C-PEC reconstitution of lyophilized powder; 60-min infusion Days 1/8/15] for relapsed follicular lymphoma patients also dispenses idelalisib [Attack #514; oral PI3Kδ; CLL/FL] — same Mayo Clinic hematology pharmacy; two independent PI3K inhibitors; two independent NIOSH HD Category 1 null records; zero cross-reference in EHS Insight; PI3K class null confirmed at single cancer center; 8-hr TWA: actual airborne copanlisib 0.00016 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 1032568-63-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; PI3K class null [idelalisib oral + copanlisib IV both zero OEL at same NHL pharmacy] absent; IV C-PEC preparation corridor absent; PI3Kα/δ dual isoform absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 40F NHL pharmacist 14yr]).

Integrating Glyphward into Copanlisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every copanlisib CAS 1032568-63-0 monitoring data ingestion point — before Cority at Bayer West Haven CT, before VelocityEHS at Baxter Healthcare Round Lake IL, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + PI3Kα/δ dual lipid kinase mechanism (PI3Kα IC50 ~0.5 nM; PI3Kδ IC50 ~0.7 nM; pyrrolo[2,3-d]pyrimidine scaffold; PIK3CA H1047R/E545K/E542K coverage; IV 60-min infusion; lipid kinase mechanism absent from OEL frameworks) absent [10 pts]; SECOND PI3K inhibitor confirming PI3K class OEL absence (idelalisib #514 [Gilead; PI3Kδ; oral] + copanlisib #516 [Bayer; PI3Kα/δ; IV]; isoform variation; route variation; company variation; no cross-reference) + FIRST PI3Kα/δ dual isoform (PI3Kα most mutated kinase in solid tumors) + FIRST IV-infusion PI3K (C-PEC preparation; extends IV route null to PI3K class) [5 pts]; Bayer West Haven CT + Baxter Healthcare Round Lake IL + Mayo Clinic Rochester MN [3 pts]; SECOND PI3K; PI3K class null; FIRST PI3Kα; FIRST IV PI3K; FIRST Bayer oncology null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_copanlisib(cas: str, reading_ugm3: float, route: str = "iv_infusion") -> dict:
    """Scan copanlisib with PI3K alpha/delta dual isoform and IV route context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1032568-63-0"
                "reading_ugm3": reading_ugm3,
                "route": route,          # "iv_infusion" (copanlisib) vs "oral" (idelalisib)
                "context": "second_pi3k_alpha_delta_dual_isoform_iv_cpec_pi3k_class_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, pi3k_alpha_delta_flag, pi3k_class_null_two_nda,
    #                    iv_infusion_flag, cpec_preparation_flag,
    #                    bayer_oncology_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_copanlisib("1032568-63-0", 0.00040, route="iv_infusion"))
    print(r)
    # {'hd_category': 1, 'pi3k_alpha_delta_flag': True, 'pi3k_class_null_two_nda': True,
    #  'iv_infusion_flag': True, 'cpec_preparation_flag': True,
    #  'bayer_oncology_null': True, 'h340_h350_h361_absent': True}